• 1. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 2. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 3. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 4. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 5. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers

Professional Introduction to Compound with CAS No. 300821-55-0 and Product Name: 2-(2-ethoxyphenoxy)acetohydrazide

2-(2-ethoxyphenoxy)acetohydrazide, identified by its CAS number 300821-55-0, is a specialized chemical compound that has garnered significant attention in the field of pharmaceutical research and development. This compound belongs to a class of molecules that exhibit potential bioactivity, making it a subject of extensive study in medicinal chemistry. The structural features of 2-(2-ethoxyphenoxy)acetohydrazide include an ethoxyphenyl group and an acetohydrazide moiety, which are known to contribute to its unique chemical properties and biological interactions.

The ethoxyphenyl group, a substituted aromatic ring, is often associated with various pharmacological effects due to its ability to interact with biological targets. In contrast, the acetohydrazide functional group is frequently utilized in the synthesis of bioactive molecules due to its reactivity and potential to form hydrogen bonds. These structural components make 2-(2-ethoxyphenoxy)acetohydrazide a promising candidate for further investigation in drug discovery.

In recent years, there has been a growing interest in the development of novel compounds that can modulate biological pathways associated with diseases such as cancer, inflammation, and neurological disorders. The unique structure of 2-(2-ethoxyphenoxy)acetohydrazide has prompted researchers to explore its potential applications in these areas. For instance, studies have suggested that compounds with similar structural motifs may interfere with key enzymatic processes or receptor binding, thereby offering therapeutic benefits.

One of the most compelling aspects of 2-(2-ethoxyphenoxy)acetohydrazide is its potential as a scaffold for drug design. By modifying its structure, researchers can fine-tune its properties to enhance its efficacy and selectivity. This approach has been successfully employed in the development of several drugs that have reached clinical use. The versatility of 2-(2-ethoxyphenoxy)acetohydrazide makes it an attractive starting point for further chemical modifications and biological evaluations.

Recent advancements in computational chemistry have also contributed to the study of 2-(2-ethoxyphenoxy)acetohydrazide. Molecular modeling techniques allow researchers to predict the interactions between this compound and biological targets with high precision. These predictions can guide experimental efforts and help identify potential lead compounds for further development. The integration of computational methods with traditional experimental approaches has significantly accelerated the drug discovery process.

The synthesis of 2-(2-ethoxyphenoxy)acetohydrazide involves multi-step organic reactions that require careful optimization to ensure high yield and purity. The synthesis typically begins with the preparation of the ethoxyphenyl intermediate, followed by functionalization with the acetohydrazide group. Advanced synthetic methodologies, such as catalytic hydrogenation and palladium-catalyzed cross-coupling reactions, have been employed to improve the efficiency of these processes.

In addition to its synthetic challenges, another important consideration is the pharmacokinetic profile of 2-(2-ethoxyphenoxy)acetohydrazide. Understanding how a compound is absorbed, distributed, metabolized, and excreted (ADME) is crucial for determining its potential as a drug candidate. Preclinical studies have begun to explore these aspects, providing valuable insights into the compound's behavior in vivo.

The safety profile of 2-(2-ethoxyphenoxy)acetohydrazide is also a critical factor in its development. Initial toxicity studies have been conducted to assess its potential adverse effects. These studies involve both in vitro and in vivo assays that evaluate various parameters such as acute toxicity, chronic toxicity, and carcinogenicity. The results from these studies will help determine whether further development is warranted.

One area where 2-(2-ethoxyphenoxy)acetohydrazide shows particular promise is in the treatment of inflammatory diseases. Inflammatory processes are central to many chronic conditions, including arthritis and autoimmune disorders. Research has indicated that compounds targeting inflammatory pathways can provide significant therapeutic benefits. The structural features of 2-(2-ethoxyphenoxy)acetohydrazide suggest that it may interact with inflammatory mediators or enzymes, potentially modulating immune responses.

Another emerging application for 2-(2-ethoxyphenoxy)acetohydrazide is in oncology research. Cancer cells often exhibit altered metabolic pathways that can be exploited for therapeutic purposes. Studies have explored the use of hydrazides as inhibitors of key enzymes involved in cancer metabolism. The ability of 2-(2-ethoxyphenoxy)acetohydrazide to interact with these enzymes makes it a candidate for further investigation as an anti-cancer agent.

The future direction of research on (CAS No 300821-55-0) will likely involve both interdisciplinary collaborations and innovative experimental designs. By combining expertise from medicinal chemistry, pharmacology, and computational biology, researchers can accelerate the discovery process and bring new treatments to patients more quickly.

• 21953-91-3(2-(4-methoxyphenoxy)acetohydrazide)
• 436155-36-1(2-(3-Methoxyphenoxy)acetohydrazide)
• 4664-55-5(2-phenoxyacetohydrazide)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)